MX2020001167A - Metodos y composiciones para el tratamiento de enfermedades por deposicion amiloide. - Google Patents

Metodos y composiciones para el tratamiento de enfermedades por deposicion amiloide.

Info

Publication number
MX2020001167A
MX2020001167A MX2020001167A MX2020001167A MX2020001167A MX 2020001167 A MX2020001167 A MX 2020001167A MX 2020001167 A MX2020001167 A MX 2020001167A MX 2020001167 A MX2020001167 A MX 2020001167A MX 2020001167 A MX2020001167 A MX 2020001167A
Authority
MX
Mexico
Prior art keywords
treatment
methods
amyloid deposition
deposition diseases
amyloid
Prior art date
Application number
MX2020001167A
Other languages
English (en)
Inventor
Suzanne Lentzsch
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MX2020001167A publication Critical patent/MX2020001167A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se divulgan procedimientos y composiciones farmacéuticas para el tratamiento de enfermedades por deposición de amiloide mediante el uso de anticuerpo quimérico (por ejemplo, ratón-humano) que incluyen un método para tratar enfermedades por deposición de amiloide con compromiso cardíaco mediante la administración de composiciones farmacéuticas que comprenden un anticuerpo de fibrilla anti-amiloide quimérico. Los procedimientos en la presente memoria pueden mejorar la función miocárdica en pacientes diagnosticados con amiloidosis de cadena ligera (ALA) que tienen un compromiso cardíaco en tan solo tres semanas después del tratamiento.
MX2020001167A 2017-08-01 2018-07-24 Metodos y composiciones para el tratamiento de enfermedades por deposicion amiloide. MX2020001167A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539821P 2017-08-01 2017-08-01
US201862637609P 2018-03-02 2018-03-02
PCT/US2018/043374 WO2019027721A2 (en) 2017-08-01 2018-07-24 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DISEASE DISEASES

Publications (1)

Publication Number Publication Date
MX2020001167A true MX2020001167A (es) 2020-11-11

Family

ID=65231894

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001167A MX2020001167A (es) 2017-08-01 2018-07-24 Metodos y composiciones para el tratamiento de enfermedades por deposicion amiloide.

Country Status (12)

Country Link
US (2) US11382974B2 (es)
EP (1) EP3661553A4 (es)
JP (2) JP2020529990A (es)
KR (3) KR20200033309A (es)
CN (1) CN111867626A (es)
AU (1) AU2018311688B2 (es)
BR (1) BR112020002155A2 (es)
CA (1) CA3071817A1 (es)
IL (1) IL272321A (es)
MX (1) MX2020001167A (es)
RU (1) RU2746812C1 (es)
WO (1) WO2019027721A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019015914A (es) * 2017-06-29 2020-08-06 Univ Columbia Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
MA55209A (fr) 2019-03-05 2022-01-12 Prothena Biosciences Ltd Procédés de traitement de l'amylose al
AU2021208630A1 (en) * 2020-01-17 2022-07-21 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid
JP2023541191A (ja) * 2020-09-14 2023-09-28 ケーラム バイオサイエンシーズ， インコーポレイテッド アミロイドーシスを治療する方法
EP4237005A1 (en) * 2020-10-28 2023-09-06 Novo Nordisk A/S Anti-transthyretin antibodies and methods of use thereof
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
KR20240058050A (ko) * 2021-05-18 2024-05-03 유니버시티 오브 테네시 리서치 파운데이션 아밀로이드 장애 치료를 위한 항체-펩티드 융합 단백질

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
JP2002515235A (ja) 1998-05-21 2002-05-28 ザ ユニヴァーシティ オブ テネシー リサーチ コーポレイション 坑アミロイド抗体を用いるアミロイドの除去方法
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP2298807A3 (en) 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
CN101421303B (zh) 2006-03-23 2013-06-12 生命北极神经科学公司 改进的初原纤维选择性抗体及其用途
UA94734C2 (ru) 2006-03-30 2011-06-10 Глаксо Груп Лимитед ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
EP2074145B1 (en) 2006-10-02 2017-08-16 AC Immune S.A. Humanized antibody against amyloid beta
US8323647B2 (en) 2007-09-13 2012-12-04 Delenex Therapeutics Ag Humanized antibodies against the β-amyloid peptide
KR101603076B1 (ko) 2007-12-28 2016-03-14 프로테나 바이오사이언시즈 리미티드 아밀로이드증의 치료 및 예방
US8195594B1 (en) 2008-02-29 2012-06-05 Bryce thomas Methods and systems for generating medical reports
US20090297439A1 (en) 2008-06-02 2009-12-03 Metheresis Translational Research Sa, Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
SG11201401360XA (en) * 2011-10-25 2014-05-29 Onclave Therapeutics Ltd Antibody formulations and methods
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
EP3186273A4 (en) 2014-08-26 2018-05-02 University of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
MX2017014810A (es) 2015-05-20 2018-05-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
WO2017184973A1 (en) 2016-04-22 2017-10-26 University Of Tennessee Research Foundation Identifying amyloidogenic proteins & amyloidogenic risk
MX2019015914A (es) * 2017-06-29 2020-08-06 Univ Columbia Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.

Also Published As

Publication number Publication date
US20190038745A1 (en) 2019-02-07
EP3661553A2 (en) 2020-06-10
CN111867626A (zh) 2020-10-30
KR20200033309A (ko) 2020-03-27
EP3661553A4 (en) 2021-06-02
AU2018311688B2 (en) 2022-02-17
CA3071817A1 (en) 2019-02-07
KR20240046269A (ko) 2024-04-08
IL272321A (en) 2020-03-31
US11382974B2 (en) 2022-07-12
BR112020002155A2 (pt) 2020-07-28
WO2019027721A3 (en) 2020-03-26
KR20230007531A (ko) 2023-01-12
JP2022104998A (ja) 2022-07-12
JP2020529990A (ja) 2020-10-15
RU2746812C1 (ru) 2021-04-21
US20230114726A1 (en) 2023-04-13
WO2019027721A2 (en) 2019-02-07
AU2018311688A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
MX2020001167A (es) Metodos y composiciones para el tratamiento de enfermedades por deposicion amiloide.
PH12021550023A1 (en) Humanized anti-tau antibodies
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CO2018013500A2 (es) Anticuerpos anti-pd-l1 y usos de los mismos
EA202092410A1 (ru) Конъюгаты камптотецина с пептидом
MX2021009053A (es) Anticuerpo monoclonal recombinante para usarse en el tratamiento de la enfermedad de alzheimer.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
AR101740A1 (es) Terapia de combinación y composiciones
BR112016030541A2 (pt) métodos para o tratamento de infecções fúngicas
AR105938A1 (es) Anticuerpo anti-epha4
PH12019501104A1 (en) Novel anti-human muc1 antibody fab fragment
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CO2019003865A2 (es) Proteína terapéutica
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
AR115192A1 (es) Anticuerpos
BR112016023011A2 (pt) tratamento de câncer gástrico
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EP3840749A4 (en) METHODS OF TREATMENT OF HEART VALVE DISEASES
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
EA201990559A1 (ru) Комбинированная терапия